Drug induced acute pancreatitis
ICD-10 K85.3 is a used to indicate a diagnosis of drug induced acute pancreatitis.
Drug-induced acute pancreatitis is an inflammatory condition of the pancreas that occurs as a result of exposure to certain medications. Clinically, patients may present with severe abdominal pain, nausea, vomiting, and elevated serum amylase and lipase levels. The anatomy involved includes the pancreas, which is located in the retroperitoneal space and plays a crucial role in digestion and glucose metabolism. Disease progression can vary; in mild cases, symptoms may resolve with discontinuation of the offending drug, while severe cases can lead to complications such as necrotizing pancreatitis or systemic inflammatory response syndrome (SIRS). Diagnostic considerations include a thorough medication history, imaging studies such as ultrasound or CT scans to assess pancreatic inflammation, and laboratory tests to evaluate pancreatic enzyme levels. Identifying the specific drug responsible is essential for effective management and prevention of recurrence.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
K85.3 specifically covers acute pancreatitis that is directly attributed to drug exposure. This includes reactions to medications such as certain antibiotics, diuretics, and immunosuppressants. The diagnosis requires a clear link between the drug and the onset of pancreatitis.
K85.3 should be used when there is clear evidence that acute pancreatitis is caused by a specific drug. If pancreatitis is due to other factors such as alcohol use or gallstones, other codes like K85.0 or K85.2 should be used.
Documentation should include a comprehensive medication history, clinical findings consistent with acute pancreatitis, laboratory results showing elevated pancreatic enzymes, and imaging studies if performed. Clear notation of the suspected drug and the timeline of exposure is crucial.
